FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136223509> ?p ?o ?g. }

• W3136223509 endingPage "416" @default.
• W3136223509 startingPage "405" @default.
• W3136223509 abstract "A first-in-human study of [18F]-BF3-Cy3-ACUPA, a small-molecule imaging agent that can be unimolecularly both positron emitting and fluorescent, is conducted to determine its safety, biodistribution, radiation dosimetry, feasibility in tumor detection by preoperative positron emission tomography (PET), as well as its intraoperative fluorescence imaging utility in patients with prostate-specific membrane antigen positive (PSMA+) tumors.Ten patients aged 66 ± 7 years received a 6.5 ± 3.2 mCi intravenous injection of [18F]-BF3-Cy3-ACUPA and underwent PET/computed tomography (CT) imaging. Radiation dosimetry of [18F]-BF3-Cy3-ACUPA, normal organ biodistribution, and tumor uptakes were examined. Two patients were prescheduled for radical prostatectomy (RP) with extended pelvic lymphadenectomy approximately 24 hours following [18F]-BF3-Cy3-ACUPA injection and imaging. Without reinjection, intraoperative fluorescence imaging was performed on freshly excised tissue during RP. Frozen sections of excised tissue during RP were submitted for confirmatory histopathology and multiphoton fluorescence and brightfield microscopy.Absorbed doses by organs including the kidneys and salivary glands were similar to 68Ga-PSMA-11 imaging. [18F]-BF3-Cy3-ACUPA physiologic radiotracer accumulation and urinary/biliary excretion closely resembled the distribution of other published PSMA tracers including [18F]-JK-PSMA-7, [18F]-PSMA-1007, [18F]-DCFPyL, and [18F]-DCFBC. 19F-BF3-Cy3-ACUPA was retained in PSMA+ cancer tissues in patients for at least 24 hours, allowing for intraoperative fluorescence assessment of the prostate and of the embedded prostate cancer without contrast reinjection. After 24 hours, the imaging agent mostly decayed or cleared from the blood pool. Preoperative PET and fluorescence imaging findings were confirmed with final histopathology and multiphoton microscopy.Our first-in-human results demonstrate that [18F]-BF3-Cy3-ACUPA is safe and feasible in humans. Larger trials with this PET tracer are expected to further define its capabilities and its clinical role in the management of PSMA+ tumors, especially in prostate cancer." @default.
• W3136223509 created "2021-03-29" @default.
• W3136223509 creator A5004173282 @default.
• W3136223509 creator A5011834144 @default.
• W3136223509 creator A5012851680 @default.
• W3136223509 creator A5012982577 @default.
• W3136223509 creator A5020903785 @default.
• W3136223509 creator A5022596326 @default.
• W3136223509 creator A5025902004 @default.
• W3136223509 creator A5028617589 @default.
• W3136223509 creator A5028629610 @default.
• W3136223509 creator A5039476835 @default.
• W3136223509 creator A5039604200 @default.
• W3136223509 creator A5045318472 @default.
• W3136223509 creator A5049438949 @default.
• W3136223509 creator A5050784583 @default.
• W3136223509 creator A5068285584 @default.
• W3136223509 creator A5077689986 @default.
• W3136223509 creator A5077792315 @default.
• W3136223509 creator A5081560725 @default.
• W3136223509 creator A5082504366 @default.
• W3136223509 date "2021-10-01" @default.
• W3136223509 modified "2023-10-12" @default.
• W3136223509 title "Small Molecule, Multimodal, [18F]-PET and Fluorescence Imaging Agent Targeting Prostate-Specific Membrane Antigen: First-in-Human Study" @default.
• W3136223509 cites W1997655323 @default.
• W3136223509 cites W2026714121 @default.
• W3136223509 cites W2034401114 @default.
• W3136223509 cites W2057116602 @default.
• W3136223509 cites W2075412330 @default.
• W3136223509 cites W2078998173 @default.
• W3136223509 cites W2089148358 @default.
• W3136223509 cites W2100287343 @default.
• W3136223509 cites W2146345509 @default.
• W3136223509 cites W2287180032 @default.
• W3136223509 cites W2328465604 @default.
• W3136223509 cites W2406484612 @default.
• W3136223509 cites W2790765246 @default.
• W3136223509 cites W2794774625 @default.
• W3136223509 cites W2800676252 @default.
• W3136223509 cites W2801092177 @default.
• W3136223509 cites W2810081026 @default.
• W3136223509 cites W2889903032 @default.
• W3136223509 cites W2904826557 @default.
• W3136223509 cites W2929289764 @default.
• W3136223509 cites W2946086183 @default.
• W3136223509 cites W2975529508 @default.
• W3136223509 cites W2995213399 @default.
• W3136223509 doi "https://doi.org/10.1016/j.clgc.2021.03.011" @default.
• W3136223509 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8449790" @default.
• W3136223509 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33879400" @default.
• W3136223509 hasPublicationYear "2021" @default.
• W3136223509 type Work @default.
• W3136223509 sameAs 3136223509 @default.
• W3136223509 citedByCount "11" @default.
• W3136223509 countsByYear W31362235092021 @default.
• W3136223509 countsByYear W31362235092022 @default.
• W3136223509 countsByYear W31362235092023 @default.
• W3136223509 crossrefType "journal-article" @default.
• W3136223509 hasAuthorship W3136223509A5004173282 @default.
• W3136223509 hasAuthorship W3136223509A5011834144 @default.
• W3136223509 hasAuthorship W3136223509A5012851680 @default.
• W3136223509 hasAuthorship W3136223509A5012982577 @default.
• W3136223509 hasAuthorship W3136223509A5020903785 @default.
• W3136223509 hasAuthorship W3136223509A5022596326 @default.
• W3136223509 hasAuthorship W3136223509A5025902004 @default.
• W3136223509 hasAuthorship W3136223509A5028617589 @default.
• W3136223509 hasAuthorship W3136223509A5028629610 @default.
• W3136223509 hasAuthorship W3136223509A5039476835 @default.
• W3136223509 hasAuthorship W3136223509A5039604200 @default.
• W3136223509 hasAuthorship W3136223509A5045318472 @default.
• W3136223509 hasAuthorship W3136223509A5049438949 @default.
• W3136223509 hasAuthorship W3136223509A5050784583 @default.
• W3136223509 hasAuthorship W3136223509A5068285584 @default.
• W3136223509 hasAuthorship W3136223509A5077689986 @default.
• W3136223509 hasAuthorship W3136223509A5077792315 @default.
• W3136223509 hasAuthorship W3136223509A5081560725 @default.
• W3136223509 hasAuthorship W3136223509A5082504366 @default.
• W3136223509 hasBestOaLocation W31362235091 @default.
• W3136223509 hasConcept C121332964 @default.
• W3136223509 hasConcept C121608353 @default.
• W3136223509 hasConcept C126322002 @default.
• W3136223509 hasConcept C126838900 @default.
• W3136223509 hasConcept C142724271 @default.
• W3136223509 hasConcept C150903083 @default.
• W3136223509 hasConcept C20417620 @default.
• W3136223509 hasConcept C207001950 @default.
• W3136223509 hasConcept C2775842073 @default.
• W3136223509 hasConcept C2776235491 @default.
• W3136223509 hasConcept C2777807558 @default.
• W3136223509 hasConcept C2778172261 @default.
• W3136223509 hasConcept C2779466945 @default.
• W3136223509 hasConcept C2780192828 @default.
• W3136223509 hasConcept C2989005 @default.
• W3136223509 hasConcept C544855455 @default.
• W3136223509 hasConcept C57477423 @default.
• W3136223509 hasConcept C62520636 @default.
• W3136223509 hasConcept C71924100 @default.
• W3136223509 hasConcept C86803240 @default.

• next